



PFIZER

4D Pharma

Pipeline • Products • Performance • Potential

CONTENTS

News	2
Latest Results	3
EXECUTIVE SUMMARY	7
Introduction	7
Current Financial Position	8
Company Performance.....	8
Business Segment Performance	10
Geographic Segment Performance	13
Company Strategy	15
R&D Strategy	16
Mergers, Acquisitions and Divestitures	17
Key Agreements	20
Discontinued Agreements.....	20
Production	21
Employees.....	21
Product Performance Forecast	23
Discontinued Products.....	25
Pipeline Analysis	26
Discontinued R&D Projects.....	26
Conclusions / Outlook	28
THERAPEUTIC AREA FOCUS	33
R&D PIPELINE	36
CARDIOVASCULAR / METABOLISM	39
Marketed Products	39
Champix	39
Lipitor	41
Norvasc.....	53
Others	58
R&D Projects	59
Apixaban	59
NOX-B11	61
PF-734200	61
Growth Forecast	62
CENTRAL NERVOUS SYSTEM	63
Marketed Products	63
Aricept.....	63
Geodon/Zeldox	67
Lyrica	70
Zoloft.....	74
Others	78
R&D Projects	79
Dimebon	79
PF-4360365	80
PF-4856880.....	81
PF-4856881	82
S,S-reboxetine.....	82
TS-032	82
Growth Forecast	83
INFECTIOUS AND RESPIRATORY	84

Marketed Products	84
Eraxis/Ecalta.....	84
Selzentry/Celsentri.....	86
Vfend	88
Zyvox/Zyvoxa.....	90
Others	92
R&D Projects	94
R343	94
Sulopenem	95
TT-033	95
UK-453061	95
Zeven.....	95
Growth Forecast	96
UROLOGY	97
Marketed Products	97
Detrusitol/Detrol	97
Toviaz.....	99
Viagra/Revatio.....	99
R&D Projects	105
PD-299685.....	105
PF-3274167	105
Growth Forecast	106
ARTHRITIS AND PAIN	107
Marketed Products	107
Celebrex/Celebra	107
R&D Projects	115
ADL5747	115
ADL5859.....	116
CCR2 Antagonists	116
CP-690550	116
Tanezumab.....	117
Growth Forecast	118
ONCOLOGY	119
Marketed Products	119
Sutent.....	119
Others	125
R&D Projects	126
Axitinib	127
CovX 060	128
Figitumumab.....	128
PD-325901	129
PD-332991	130
PF-3512676	130
PF-4949568	130
Growth Forecast	132
OPHTHALMOLOGY	133
Marketed Products	133
Xalatan/Xalcom/Xalacom	133
Others	135
R&D Projects	137
PF-4523655	137

T2-TrpRS	137	Medivation Inc	178
Growth Forecast.....	138	Melior Discovery Inc.....	178
ENDOCRINE DISORDERS.....	139	Merck KGaA.....	178
Marketed Products	139	NicOx SA.....	179
Genotropin	139	NovaMed Pharmaceuticals Inc.....	181
Growth Forecast.....	144	Novocell.....	182
WOMEN'S HEALTHCARE	145	Noxxon Pharma AG.....	182
Marketed Products	145	Odyssey Thera Inc.....	182
Fablyn.....	145	Onyx Pharmaceuticals Inc.....	182
Others	146	OSI Pharmaceuticals Inc/New York University.....	183
R&D Projects.....	147	Quark Pharmaceuticals Inc	184
CP-533536.....	147	Recordati	184
Growth Forecast.....	148	Renovis Inc.....	184
OTHER.....	149	Rigel Pharmaceuticals Inc	185
Marketed Products	149	Sigma-Tau Pharmaceuticals Inc.....	186
Zyrtec/Reactine	149	Silence Therapeutics	187
R&D Projects.....	152	Tacere Therapeutics	187
Xiaflex.....	152	Taisho Pharmaceutical.....	187
APPENDIX 1 - FINANCIAL PERFORMANCE	155	TransTech Pharma	188
Full Year Results 2008.....	155	UCB.....	188
APPENDIX 2 - KEY CORPORATE EVENTS	158	Others	189
APPENDIX 3 - KEY AGREEMENTS.....	161	APPENDIX 4 - INFRASTRUCTURE.....	190
Adolor Corporation	162	Manufacturing Facilities.....	190
Allergan	162	R&D Facilities.....	195
Almirall SA	163	APPENDIX 5 - KEY PHARMACEUTICAL	
Astellas Pharma Inc	163	SUBSIDIARIES/JOINT VENTURES.....	197
Aurobindo Pharma/Claris Lifesciences Ltd.....	164	Subsidiaries	197
Auxillium Holdings Inc	165	Joint-venture Companies	199
Bausch & Lomb Inc	165	APPENDIX 6 - PRODUCT INDEX	201
Bayer Schering Pharma.....	166		
Boehringer Ingelheim	166		
Bristol-Myers Squibb.....	166		
Celldex Therapeutics	167		
Coley Pharmaceutical Group Inc.....	168		
Cytos Biotechnology AG	168		
Eisai	169		
Elusys Therapeutics	169		
Five Prime Therapeutics Inc	170		
Genentech Inc	170		
GlaxoSmithKline.....	170		
Graceway Pharmaceuticals LLC.....	171		
Hydra Biosciences Inc	172		
Icagen Inc.....	172		
Immunicon Corporation.....	173		
Incyte Corporation.....	173		
International Partnership for Microbicides	174		
Isis Pharmaceuticals Inc.....	174		
Lavipharm Co	175		
Ligand Pharmaceuticals Inc.....	175		
Kosan Biosciences	176		
Medarex Inc	177		

INDEX OF TABLES

<i>Principal Operating Results</i>	1
<i>Capital Expenditure By Business Area</i>	9
<i>Sales By Business Area</i>	10
<i>Operating Income By Business Area</i>	11
<i>Identifiable Assets By Business Area</i>	12
<i>Sales By Destination</i>	13
<i>Long-Lived Assets By Geographical Area</i>	13
<i>Key Patent Expiry Dates</i>	23
<i>Recent Product Approvals</i>	25
<i>Sales By Therapeutic Area/Major Products</i>	33
<i>Breakdown Of Cardiovascular/Metabolic Product Sales</i>	39
<i>Major Cardiovascular/Metabolism Products, 2008</i>	39
<i>Breakdown of CNS Sales</i>	63
<i>Major CNS Products, 2008</i>	63
<i>Breakdown of Infectious Disease/ Respiratory Sales</i>	84
<i>Major Infectious & Respiratory Products, 2008</i>	84
<i>Breakdown of Urology Sales</i>	97
<i>Major Urology Products, 2008</i>	97
<i>Breakdown of Arthritis/Pain Sales</i>	107
<i>Major Arthritis and Pain Products, 2008</i>	107
<i>Breakdown of Oncology Sales</i>	119
<i>Major Oncology Products, 2008</i>	119
<i>Breakdown of Ophthalmology Sales</i>	133
<i>Major Ophthalmology Products, 2008</i>	133
<i>Breakdown of Endocrine Sales</i>	139
<i>Major Endocrine Disorder Products, 2008</i>	139
<i>Breakdown of Other Product Sales</i>	149
<i>Major Other Products, 2008</i>	149
<i>Pfizer's Major Manufacturing Sites</i>	191

INDEX OF CHARTS

<i>Sales, Costs and Operating Income</i>	8
<i>R&D Expenditure & Capital Expenditure</i>	9
<i>Capital Expenditure By Business Area</i>	9
<i>Sales By Business Area</i>	10
<i>Operating Income By Business Area</i>	11
<i>Sales By Destination</i>	13
<i>Employees and Productivity</i>	22
<i>Sales of Current Top Ten Products (2003A-2013E)</i>	24
<i>Sales By Therapeutic Area</i>	34
<i>Top Selling Products, 2008</i>	35
<i>Champix Sales (2006A-2013E)</i>	41
<i>Lipitor Sales (2003A-2013E)</i>	49
<i>Norvasc Sales (2003A-2013E)</i>	57
<i>Apixaban Sales (2010E-2014E)</i>	60
<i>Aricept Sales (2003A-2013E)</i>	67
<i>Geodon/Zeldox Sales (2003A-2013E)</i>	70
<i>Lyrica Sales (2004A-2013E)</i>	73
<i>Zoloft Sales (2003A-2013E)</i>	77
<i>Selzentry/Celsentri Sales (2007A-2013E)</i>	87
<i>Vfend Sales (2003A-2013E)</i>	90
<i>Zyvox Sales (2003A-2013E)</i>	92
<i>Detrol/Detrol LA Sales (2003A-2013E)</i>	99
<i>Viagra Sales (2003A-2013E)</i>	104
<i>Celebrex Sales (2003A-2013E)</i>	113
<i>Sutent Sales (2006A-2013E)</i>	123
<i>Sales Forecast (2010E-2015E)</i>	127
<i>Xalatan/Xalcom Sales (2003A-2013E)</i>	135
<i>Genotropin Sales (2003A-2013E)</i>	143
<i>Fablyn Sales (2010E-2015E)</i>	145
<i>Sales, Costs and Operating Income</i>	156
<i>Profitability and Research Ratios</i>	156
<i>R&D Expenditure and Capital Expenditure</i>	156
<i>Current Assets, Liabilities and Ratio</i>	157
<i>Assets, Cash and Liquidity</i>	157
<i>Employees and Productivity</i>	157